The advent of antibody drug conjugates have been an exciting advancement for the treatment of metastatic breast cancer, as certain drugs can work in ...

Patients with relapsed or refractory KMT2A rearranged acute leukemia obtained durable minimal residual disease (MRD)-negative remission rates as a result of ...

Patients with multiple myeloma are at a higher risk of facing financial burdens due to treatment costs; however, financial support services may be accessed ...

I had recently came across an article posted by the Epoch Times mentioning a study done on mice. In the study, a nutrient discovered in dairy and meat ...

The novel cell therapy Orca-Q demonstrated early signals of relapse-free and overall survival benefits, in addition to an acceptable side effect profile, in ...

Despite their pre-clinical safety data, Mellor says, “We had to go in at a really, really low dose.” The first two volunteers received only 70 ...

Patients with B-cell malignancies who were intolerant to prior treatment with Calquence (acalabrutinib) experienced clinically meaningful benefits with ...

The last week was a busy one for us here at CURE® and across the oncology space in general. There were two major meetings we covered: the San Antonio Breast ...

Treatment with Kymriah (tisagenlecleucel) showed responses lasting more than three years in patients with relapsed/refractory follicular lymphoma, according ...

Recent research showed that social determinants of health may influence the treatments that patients with chronic lymphocytic leukemia (CLL) or small ...